A federal appeals court yesterday upheld a win for Medtronic (NYSE:MDT) subsidiary Cardiocom in a patent battle with Robert Bosch Healthcare Systems.
The U.S. Court of Appeals for the Federal Circuit upheld rulings by the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board that invalidated a trio of Bosch patents.
Bosch had alleged that the electronic data collection system used with Cardiocom’s chronic disease management platform violated U.S. patents 7,516,192 (Networked system for interactive communication and remote monitoring of individuals), 7,840,420 (Multiple patient monitoring system for proactive health management) and 7,921,186 (Networked system for interactive communication and remote monitoring of individuals).
The PTAB ruled in January 2015 that the patents were unpatentable as obvious in light of prior art. Bosch appealed, but the Federal Circuit yesterday upheld the PTAB decisions without comment in a per curiam decision.
Fridley, Minn.-based Medtronic bought Cardiocom for $200 million in cash in August 2013 in a bid to get into the disease management business.
Chanhassen, Minn.-based Cardiocom makes devices aimed at helping to manage chronic conditions like diabetes or heart disease.
